financetom
Business
financetom
/
Business
/
What's Going On With Enphase Energy (ENPH) Stock?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Enphase Energy (ENPH) Stock?
Jul 23, 2024 12:48 PM

Enphase Energy Inc ( ENPH ) shares are trading higher by 0.35% to $105.11 Tuesday. Traders and investors are watching for the company’s second-quarter earnings report, which is confirmed for Tuesday’s after-hours session. According to analyst consensus estimates, Enphase is expected to report EPS of 48 cents on revenue of $309.67 million.

Given disappointing first-quarter results, any improvement or further decline in U.S. and European revenue will be crucial. Investors will want to see if the European growth can offset the continued softness in the U.S. market.

Updates on U.S. demand and any signs of recovery or further softening will be critical. The company's efforts to manage channel inventory and its impact on shipments will also be closely watched.

Enphase’s ability to maintain or improve its gross margin within the projected range of 42% to 45% will be significant, particularly in the face of fluctuating demand and potential pricing pressures.

Any updates or changes to the company’s guidance for the remainder of the year will also be a focal point. Clear and positive guidance can help restore investor confidence despite the first-quarter setbacks.

Read Also: Top Trader Flags Key Factors To Watch For The Ethereum ETF Trading Launch

Is ENPH A Good Stock To Buy?

When deciding whether to buy a stock, there are some key fundamentals investors may want to consider. One of these factors is revenue growth. Buying a stock is essentially a bet that the business will continue to grow and generate profits in the future.

Enphase Energy ( ENPH ) has reported average annual revenue growth of 33.97% over the past 5 years. .

It's also important to pay attention to valuation when deciding whether to buy a stock. Enphase Energy ( ENPH ) has a forward P/E ratio of 38.91. This means investors are paying $38.91 for each dollar of expected earnings in the future. The average forward P/E ratio of Enphase Energy's ( ENPH ) peers is 30.05.

Other important metrics to look at include a company's profitability, balance sheet, performance relative to a benchmark index and valuation compared to peers. For in-depth analysis tools and important financial data, check out Benzinga Pro.

According to data from Benzinga Pro, ENPH has a 52-week high of $182.26 and a 52-week low of $73.49.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Elevai Labs Unit Seeks Patents for Lead Drug Candidate to Treat Muscle Loss in Obese Patients
Elevai Labs Unit Seeks Patents for Lead Drug Candidate to Treat Muscle Loss in Obese Patients
Oct 3, 2024
08:17 AM EDT, 10/03/2024 (MT Newswires) -- Elevai Labs ( ELAB ) said Thursday that its Elevai Biosciences subsidiary filed two patent applications for its lead candidate, EL-22, to treat muscle loss in obese patients. The applications cover both standalone and combination therapies with GLP-1 receptor agonists, according to the company. A phase 1 study of EL-22 in South Korea...
Farmland Partners Sells 46-Farm Portfolio For $289M: Details
Farmland Partners Sells 46-Farm Portfolio For $289M: Details
Oct 3, 2024
Farmland Partners Inc. ( FPI ) shares are trading lower on Thursday. The company said it is selling a portfolio of 46 farms, comprising 41,554 acres of farmland, for $289 million in a single transaction with Farmland Reserve. The portfolio includes farms across several regions and states, including Arkansas, Florida, Louisiana, Mississippi, Nebraska, Oklahoma, and the Carolinas.  “Farmland is a...
Legend Biotech to Open New Cell Therapy R&D Facility in Philadelphia
Legend Biotech to Open New Cell Therapy R&D Facility in Philadelphia
Oct 3, 2024
08:19 AM EDT, 10/03/2024 (MT Newswires) -- Legend Biotech ( LEGN ) said Thursday it is constructing a new research and development site in Philadelphia, Pennsylvania for advancing its cell therapies portfolio. The company anticipates to complete the development in Q3 2025. The new facility is expected to have 55 full-time employees, the company said. Price: 48.41, Change: -0.27, Percent...
Levi Strauss shares fall on sluggish holiday quarter forecast
Levi Strauss shares fall on sluggish holiday quarter forecast
Oct 3, 2024
(Reuters) - Levi Strauss' shares slumped about 11% in premarket trading on Thursday after it forecast tepid holiday quarter revenue as the denim maker grapples with weak demand from retailers with consumers paring back spending. The company, whose stock has risen about 27% so far this year and was trading at $18.77 premarket, also said on Wednesday it was considering...
Copyright 2023-2026 - www.financetom.com All Rights Reserved